UNICA IRIS Institutional Research Information System

CAOCCI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 479.455
NA - Nord America 13.050
AS - Asia 2.355
OC - Oceania 45
AF - Africa 39
SA - Sud America 36
Continente sconosciuto - Info sul continente non disponibili 11
Totale 494.991
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 475.878
US - Stati Uniti d'America 12.936
CN - Cina 1.318
UA - Ucraina 1.125
SE - Svezia 1.054
SG - Singapore 474
FI - Finlandia 366
GB - Regno Unito 341
DE - Germania 313
VN - Vietnam 175
FR - Francia 143
IN - India 122
CA - Canada 92
KR - Corea 71
IR - Iran 40
AU - Australia 39
NL - Olanda 37
IE - Irlanda 33
RU - Federazione Russa 30
BE - Belgio 28
JP - Giappone 27
HK - Hong Kong 26
MY - Malesia 18
CZ - Repubblica Ceca 17
MX - Messico 17
TR - Turchia 15
BR - Brasile 14
PL - Polonia 14
CH - Svizzera 12
EG - Egitto 11
EU - Europa 11
IQ - Iraq 11
AR - Argentina 10
AT - Austria 10
ES - Italia 10
BG - Bulgaria 9
ID - Indonesia 8
SA - Arabia Saudita 8
PK - Pakistan 7
TN - Tunisia 7
HU - Ungheria 6
JO - Giordania 6
NZ - Nuova Zelanda 6
PH - Filippine 6
RO - Romania 6
TW - Taiwan 6
ZA - Sudafrica 6
KE - Kenya 5
LT - Lituania 5
CL - Cile 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
PA - Panama 3
PT - Portogallo 3
BD - Bangladesh 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DZ - Algeria 2
EC - Ecuador 2
LB - Libano 2
MA - Marocco 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BY - Bielorussia 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MZ - Mozambico 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 494.991
Salva come PNG Salva come JPEG
Città #
Cagliari 448.486
Uta 26.025
Fairfield 1.725
Woodbridge 1.325
Boardman 939
Ashburn 871
Houston 855
Chandler 843
Nyköping 709
Wilmington 705
Seattle 691
Ann Arbor 689
Cambridge 618
Jacksonville 591
New York 292
Beijing 256
Singapore 236
Nanjing 214
Boston 198
Helsinki 178
Dong Ket 170
Santa Clara 163
Shanghai 143
Dearborn 125
Rome 117
San Diego 115
Milan 111
Guangzhou 68
Los Angeles 68
Redwood City 67
Shenyang 64
Hebei 59
Nanchang 58
Seoul 58
Menlo Park 57
Mountain View 55
Toronto 53
Changsha 47
Norwalk 45
London 42
Atlanta 40
Tianjin 39
Jiaxing 38
Verona 35
Washington 34
Orange 33
Falls Church 29
Jinan 29
Phoenix 28
Pune 28
Sassari 26
Brussels 25
Zhengzhou 24
Auburn Hills 20
Hong Kong 20
Ningbo 18
Sydney 18
Quartu Sant'Elena 17
Redmond 17
Munich 16
Naples 16
San Jose 16
Borås 15
Hangzhou 15
Saint Petersburg 15
Wuhan 15
Hefei 14
Palermo 14
Turin 13
Bologna 12
Shenzhen 12
Ahmedabad 11
Dublin 11
Florence 11
Padova 11
Bari 10
Delhi 10
Oxford 10
Paris 10
Quartu Sant'elena 10
San Mateo 10
Baghdad 9
Frankfurt am Main 9
Kunming 9
Lappeenranta 9
Messina 9
Taizhou 9
Tokyo 9
Amsterdam 8
Augusta 8
New Delhi 8
Rio de Janeiro 8
Sestu 8
Sofia 8
Alghero 7
Andover 7
Berlin 7
Chicago 7
Hounslow 7
Hyderabad 7
Totale 489.079
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 240.349
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.415
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.491
Leucocyte classification for leukaemia detection using image processing techniques 3.396
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 3.333
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.270
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.252
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 3.224
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.202
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.201
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.108
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 2.960
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.825
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.799
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.696
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.658
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.629
Ruolo del trapianto allogenico nelle talassemie 2.609
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.519
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.477
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.420
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.207
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.107
Health related quality of life in patients with onco-hematological diseases 2.098
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.080
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.012
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 2.009
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.005
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 1.976
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 1.894
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.857
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.844
Ruxolitinib therapy and telomere length in myelofibrosis 1.825
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.810
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.773
null 1.759
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.747
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.723
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.719
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.673
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.602
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.575
Acute basophilic leukemia with U2AF1 mutation 1.529
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.487
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.485
T cell tyrosine phosphorylation response to transient redox stress 1.484
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.472
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.468
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research 1.465
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.464
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research 1.445
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.429
null 1.419
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.402
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.398
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.397
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.395
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.376
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.364
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.362
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.360
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 1.328
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.323
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.307
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 1.277
Immunological deregulation in classic hodgkin lymphoma 1.245
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.238
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.237
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.224
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.223
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.215
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: A multicentre, prospective, observational, cohort study 1.172
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes 1.140
null 1.138
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 1.133
null 1.128
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 1.126
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 1.123
null 1.110
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination 1.071
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 1.070
null 1.048
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated haematopoietic stem cell transplantation 1.043
Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment 1.041
null 1.034
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 1.026
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 1.005
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 1.004
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? 993
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? 989
null 984
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency 980
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis 976
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab 975
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone 939
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment 938
Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease 935
The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia 914
Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis 912
null 904
Totale 409.797
Salva come PNG Salva come JPEG
Categoria #
all - tutte 575.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 575.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019.472 0 0 0 0 0 8.820 4.774 1.487 1.048 911 954 1.478
2020/202156.948 1.709 2.254 2.752 13.090 10.912 6.431 5.338 3.686 1.243 4.278 3.109 2.146
2021/202217.322 1.674 1.367 820 915 1.235 1.281 835 875 1.405 2.021 2.587 2.307
2022/202322.185 1.654 2.475 2.451 1.687 2.012 2.372 961 2.724 1.364 1.400 2.052 1.033
2023/202426.605 1.275 1.050 1.468 1.954 2.229 4.706 3.680 1.828 1.345 2.031 2.505 2.534
2024/2025280.439 9.854 102.071 155.748 7.048 3.270 2.448 0 0 0 0 0 0
Totale 495.984